Advancing Pharmaceutical Innovation Through Strategic Partnership
The National University of Singapore (NUS) has strengthened its position as a leader in pharmaceutical sciences with the launch of a dedicated multi-omics laboratory in collaboration with MGI Tech Singapore. This facility, known as the Core Facility & NUS PPS - MGI Tech Multi-Omics Laboratory, integrates advanced genomic sequencing and multi-omics technologies to support cutting-edge research in drug discovery and precision medicine.
Announced in March 2026, the partnership falls under MGI's global DCS Lab initiative, which focuses on DNA genomics, cell omics, and spatial omics. The lab equips researchers and students at NUS Department of Pharmacy and Pharmaceutical Sciences (NUS PPS) with tools to explore complex biological systems at multiple levels, from DNA sequences to spatial cellular interactions.
Understanding Multi-Omics Technologies in Context
Multi-omics refers to the integrated analysis of multiple layers of biological data, including genomics (DNA), transcriptomics (RNA), proteomics (proteins), metabolomics (metabolites), and spatial omics (location-specific cellular information). This approach provides a holistic view of biological processes, which is essential for identifying drug targets and understanding disease mechanisms.
At the new laboratory, researchers can perform streamlined workflows using MGI's instrument portfolio. These tools enable high-precision experiments that were previously resource-intensive, accelerating the pace from basic research to translational applications in pharmaceutical sciences.
The Role of NUS Pharmacy and Pharmaceutical Sciences
NUS PPS, part of the NUS Faculty of Science, is Singapore's sole provider of pharmacy education. Established in 1905, the department has a long history of excellence in pharmaceutical education, research, and practice. Its vision centers on shaping healthcare through innovative approaches, making it an ideal partner for technology-driven initiatives like this multi-omics lab.
The collaboration enhances NUS PPS's capacity to train the next generation of pharmacists and researchers. Students and postgraduate researchers gain hands-on experience with state-of-the-art equipment, bridging theoretical knowledge with practical skills in drug discovery.
Key Features of the New Laboratory
The facility provides an integrated ecosystem for multi-omics research. It supports applications in precision medicine, where treatments are tailored to individual genetic profiles, and in pharmaceutical innovation, where new compounds are developed and tested more efficiently.
MGI contributes its expertise in sequencing and omics platforms, ensuring the lab operates at high performance. This setup allows for end-to-end processes, from sample preparation to data analysis, fostering interdisciplinary collaboration across NUS faculties and with industry partners.
Photo by National Cancer Institute on Unsplash
Impact on Drug Discovery Research
Drug discovery traditionally involves lengthy and costly processes. Multi-omics approaches can identify biomarkers, validate targets, and predict drug responses earlier in development. The NUS-MGI lab positions Singapore researchers to contribute meaningfully to global efforts in areas such as oncology, infectious diseases, and chronic conditions.
By combining academic rigor with industrial-grade technology, the laboratory serves as an incubator for breakthroughs that could lead to new therapeutics and improved healthcare outcomes.
Enhancing Higher Education and Research Training
Beyond research output, the lab significantly impacts higher education at NUS. It offers new opportunities for undergraduate, master's, and PhD students to engage in real-world projects. This experiential learning prepares graduates for careers in academia, biotechnology, and pharmaceutical industries.
Faculty members benefit from expanded research capabilities, potentially attracting more grants and international collaborations. The initiative aligns with Singapore's broader goals of building a knowledge-based economy through science and technology education.
Perspectives from Key Stakeholders
Dr. Liu Xin, Vice President of MGI, highlighted the partnership's potential: "We are honored to partner with NUS Pharmacy and Pharmaceutical Sciences, a world-class department pushing the boundaries of pharmaceutical science. By providing cutting-edge technology platforms—from genomics to multi-omics—we are equipping tomorrow's pharmacists and researchers with the tools to drive discovery."
Professor Giorgia Pastorin, Head of Department at NUS PPS, added: "We are proud to embark on this meaningful partnership that unites our shared commitment to scientific excellence and innovation. Together, we look forward to advancing discoveries that shape the future of healthcare and elevate the impact of translational research."
Singapore's Growing Biotech and Pharmaceutical Ecosystem
Singapore has positioned itself as a hub for biomedical sciences, with institutions like NUS playing central roles. Initiatives such as this laboratory complement national efforts in research translation and industry-academia linkages, supporting the development of a vibrant life sciences sector.
The lab's establishment reflects broader trends in higher education where universities increasingly integrate advanced technologies into curricula and research programs to remain competitive globally.
Photo by ThisisEngineering on Unsplash
Future Outlook and Opportunities for Academics
Looking ahead, the multi-omics laboratory is expected to generate new research outputs, publications, and potentially spin-off companies. It may also lead to specialized courses or modules within NUS PPS programs focused on omics technologies and data analysis.
For PhD-track job seekers and early-career academics, this development signals expanding opportunities in Singapore's higher education and research landscape, particularly in interdisciplinary fields combining pharmacy, data science, and biotechnology.
Broader Implications for Global Collaboration
As part of MGI's international DCS Lab network, the NUS facility connects Singapore researchers to a worldwide community. This fosters knowledge exchange and positions NUS as a key node in global pharmaceutical innovation networks.
The partnership exemplifies how higher education institutions in Singapore leverage strategic alliances to enhance their research infrastructure and educational offerings.